SeSA-HCPT is an orally active dual-target inhibitor integrating Topo I and HDAC inhibition. SeSA-HCPT induces potent DNA damage, apoptosis, S-phase arrest in prostate cancer cells. SeSA-HCPT inhibits cancer cells proliferation and migration. SeSA-HCPT impairs homologous recombination bysuppressing KIF4A-RAD51 signaling. SeSA-HCPT markedly inhibits CRPC tumor growth withminimal systemic toxicity[1].
Molecular Weight:
1519.37
Formula:
C76H76N6O18Se2
Target:
Apoptosis,HDAC,Kinesin,RAD51,Topoisomerase
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
